White House Drug Strategy Contradicts Trump Cannabis Policy Moves

The Trump administration's newly released drug strategy document warns against expanding cannabis access even as the White House continues pushing forward with marijuana rescheduling—a contradiction experts say reveals deep policy confusion at the federal level.

The National Drug Control Strategy, published this week, explicitly cautions about "the dangers" of liberalizing cannabis policy. Yet the administration simultaneously supports moving marijuana from Schedule I to Schedule III under the Controlled Substances Act, a move that would acknowledge medical use and ease research restrictions.

"The administration, on the one hand, is moving in a direction of liberalizing access to cannabis, but at the same time, in the strategy, it talks about the dangers of doing so," said Aneri Pattani of KFF Health News, who first reported the disconnect.

The Policy Disconnect

The contradiction extends beyond marijuana. The 120-page strategy document emphasizes harm reduction approaches for opioid addiction while maintaining hardline rhetoric on other substances. It calls for expanded access to medications like buprenorphine and naloxone for overdose prevention—evidence-based interventions the medical community has long advocated.

But the cannabis section reads like it was written by a different agency entirely. The document resurrects concerns about marijuana's health risks and questions about impaired driving, arguments typically associated with prohibition-era thinking rather than regulatory frameworks adopted by 38 medical marijuana states and 24 adult-use markets.

Industry observers note the timing couldn't be more awkward. The Drug Enforcement Administration is currently reviewing public comments on the proposed rescheduling, with a final decision expected sometime this year. Cannabis companies have invested billions in state-legal operations based partly on signals that federal policy would eventually align with state reforms.

What Industry Leaders Are Saying

Cannabis trade groups haven't yet issued formal responses to the strategy document, but private conversations reveal frustration. One dispensary operator in Michigan—who requested anonymity to speak candidly about federal policy—called it "typical Washington doublespeak."

"We've been paying effective tax rates of 70% because of 280E, we can't access normal banking, and now they're publishing documents that make us sound like fentanyl dealers," the operator said. "Pick a lane."

The mixed messaging also complicates state-level reform efforts. Legislators in states considering medical marijuana programs often look to federal guidance when crafting regulations. A White House strategy document that questions cannabis liberalization gives ammunition to opponents even as federal agencies prepare to acknowledge medical benefits through rescheduling.

The Broader Drug Policy Picture

To be fair, the strategy does represent progress on some fronts. Its embrace of syringe service programs and medication-assisted treatment marks a departure from purely punitive approaches that dominated federal drug policy for decades. The document allocates significant resources to treatment and prevention rather than just enforcement.

But drug policy experts say the cannabis contradictions undermine the strategy's credibility. If the administration can't reconcile its position on marijuana—a substance now legal in half the country—how will it handle more complex challenges around psychedelics, kratom, or emerging synthetic substances?

What Happens Next

The immediate question is whether the strategy document affects the DEA's rescheduling timeline. Agency officials have maintained the process is independent and based on scientific review rather than political considerations. The Justice Department recommended rescheduling last year after a Health and Human Services review concluded marijuana has accepted medical use.

Meanwhile, congressional cannabis reform efforts continue in parallel. Senate Majority Leader Chuck Schumer has promised another push for the SAFE Banking Act, which would protect financial institutions serving state-legal cannabis businesses. The strategy document's cautious language on marijuana could give Republican senators cover to oppose it.

For cannabis businesses operating in the $30 billion state-legal market, the contradictions mean continued uncertainty. Companies making long-term investment decisions need clarity on federal policy—not documents that simultaneously advance and question the same reforms.

The strategy is set to guide federal drug policy through 2029, meaning these contradictions could persist for years unless the administration clarifies its position.

---

This article is based on original reporting by www.marijuanamoment.net.